ArticleCureus2026
Clinical Outcomes of Extended-Release Guanfacine in Adults With Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Adult attention-deficit/hyperactivity disorder (ADHD) is a clinically important neurodevelopmental condition with a substantial global prevalence. Extended-release guanfacine (GXR) is a non-stimulant selective α2A-adrenergic receptor agonist approved for adult ADHD in Japan, but real-world adult data remain limited. Materials and methods We conducted a retrospective medical chart review of consecutive eligible adults with ADHD treated with GXR at an ADHD specialty clinic in Japan. ADHD was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria by experienced psychiatrists. Clinical Global Impression-Severity (CGI-S), GXR dose, treatment continuation at week 10, Clinical Global Impression-Improvement (CGI-I), and treatment-emergent adverse events (TEAEs) were extracted from medical records. Continuous variables were summarized as mean±standard deviation (SD) and categorical variables as number and percentage. Exact binomial 95% confidence intervals (CIs) were calculated for proportions. Exploratory baseline comparisons by treatment continuation status were performed using the Shapiro-Wilk test, Welch t-test, or Mann-Whitney U test for continuous variables and the Fisher exact test for categorical variables. Statistical analyses were performed using EZR, a graphical user interface for R. Results Among 137 participants, 111 (81%; 95% CI: 73.4-87.2%) continued GXR treatment for 10 weeks. Among the 111 participants with week-10 CGI-I data, 58 (52.3%; 95% CI: 42.6-61.8%) were rated as very much improved or much improved. TEAEs were recorded in 76 participants (55.5%; 95% CI: 46.7-64%), and no serious TEAEs were observed. Conclusions These findings suggest that GXR may be a clinically useful and generally well-tolerated treatment option for adults with ADHD in routine practice in Japan. The results support cautious real-world titration and highlight the need for prospective studies using standardized adult ADHD outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.